Skip to main content

Table 5 Analysis of the risk factors of microbiological improvement evaluated with MAC cultures

From: Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease

Variables

Total

Sputum conversion

Sputum positive

Multivariate analysis

n

(n = 12)

(n = 21)

Odds ratio

Continuation of CAM or AZM

26

10 (83)

16 (76)

1.1 (0.13–8.7)

Treatment with 3 or more drugs

21

6 (50)

15 (71)

0.57 (0.092–3.5)

Age ≥75 years*

8

6 (50)

2 (9.5)

5.7 (0.67–49)

Female

31

10 (83)

21 (100)

 

Nonsmoker

30

11 (92)

19 (90)

 

BMI 18 kg/m2

11

5 (42)

6 (29)

 

NB (radiological findings)

27

9 (75)

18 (86)

 

Total lesion extenta 1 or 2

26

9 (75)

17 (81)

 

Cavity

25

10 (83)

15 (71)

 

Albumin ≥3.5 g/dl

26

11 (92)

15 (71)

3.0 (0.22–41)

CRP <1.0 mg/dl

16

5 (42)

11 (52)

0.79 (0.12–5.2)

  1. Data are presented as no. (%)
  2. CAM clarithromycin, AZM azithromycin, NB nodular/bronchiectatic disease, BMI body mass index, CRP C-reactive protein
  3. *Significant at p < 0.05 in univariate analysis
  4. a1 within one third of unilateral lung field; 2 within unilateral lung field